Vertex Pharma (VRTX) Tops Q3 EPS by 23c, provides guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $546.12 -2.12%
Revenue Growth %: +10.7%
Financial Fact:
Royalty revenues: 3.84M
Today's EPS Names:
PMCB, CULP, HURC, More
Revenue Growth %: +10.7%
Financial Fact:
Royalty revenues: 3.84M
Today's EPS Names:
PMCB, CULP, HURC, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $4.80, $0.23 better than the analyst estimate of $4.57. Revenue for the quarter came in at $3.08 billion versus the consensus estimate of $3.05 billion.
GUIDANCE:
Vertex Pharma sees FY2025 revenue of $11.9-12 billion, versus the consensus of $12.002 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Epic Gold plans $3.15M non-brokered private placement
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
